Display options
Cite
Monaghan TM, Seekatz AM, Mullish BH, et al. . Expert Opin Ther Targets. 2021;25(11):949-963doi: 10.1080/14728222.2021.2008907.
Monaghan, T. M., Seekatz, A. M., Mullish, B. H., Moore-Gillon, C. C. E. R., Dawson, L. F., Ahmed, A., Kao, D., & Chan, W. C. (2021). . Expert opinion on therapeutic targets, 25(11), 949-963. https://doi.org/10.1080/14728222.2021.2008907
Monaghan, Tanya M, et al. "." Expert opinion on therapeutic targets vol. 25,11 (2021): 949-963. doi: https://doi.org/10.1080/14728222.2021.2008907
Monaghan TM, Seekatz AM, Mullish BH, Moore-Gillon CCER, Dawson LF, Ahmed A, Kao D, Chan WC. . Expert Opin Ther Targets. 2021 Nov;25(11):949-963. doi: 10.1080/14728222.2021.2008907. Epub 2021 Dec 02. PMID: 34793686.
Copy Download .nbib Format: NLM
Share it on

Expert Opin Ther Targets. 2021 Nov;25(11):949-963. doi: 10.1080/14728222.2021.2008907. Epub 2021 Dec 02.

[No title available]

Expert opinion on therapeutic targets

Tanya M Monaghan, Anna M Seekatz, Benjamin H Mullish, Claudia C E R Moore-Gillon, Lisa F Dawson, Ammar Ahmed, Dina Kao, Weng C Chan

Affiliations

  1. NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, UK.
  2. Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, UK.
  3. Biological Sciences, Clemson University, Clemson, SC, USA.
  4. Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.
  5. Departments of Gastroenterology and Hepatology, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK.
  6. Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK.
  7. Department of Gastroenterology, Zeidler Ledcor Centre, University of Alberta, Edmonton, Alberta, Canada.
  8. School of Pharmacy, Biodiscovery Institute, University of Nottingham, University Park, Nottingham, UK.

PMID: 34793686 DOI: 10.1080/14728222.2021.2008907

Abstract

AREAS COVERED: We searched PubMed and Web of Science databases for articles identifying novel therapeutic targets or treatments for

EXPERT OPINION: Considerable progress has been made in the development of new anti-CDI drug candidates. Nevertheless, a greater comprehension of CDI pathogenesis and host-microbe interactions is beginning to uncover potential novel therapeutic targets, which can be exploited to plug gaps in the CDI drug discovery pipeline.

Keywords: Clostridioides difficile infection; new drug targets; small inhibitors; therapeutics; toxins; virulence factors

Publication Types